Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)

Live Online Conference on 10/11 November 2020

Highlights

- European and US Guidelines and Regulatory Requirements and Inspections
- Quality and Manufacturing of CAR-T-Cells
- GMP Implementation in University and Industry – Large Scale and Small Scale
- How to Handle Out-of-Specification Batches
- Microbiological Safety and Testing
- Approaches for Small Batches and Optimising Manufacturing

Speakers

Dr Hans-Georg Eckert
Valicare

Dr Elena Ferber
Labor LS

Dr Anette Jork
BioNTech

Dr Ilona Kalaszczyńska
Medical University of Warsaw

Dr Christoph Peter
BioNTech

Dr Christoph Prinz
BioNTech

Dr Christianne Reijnders
The Dutch Health and Youth Care Inspectorate

Dr Ralf Sanzenbacher
PEI, German Federal Agency for Vaccines and Biomedicines

Mag. Gabriela Schallmeiner
Inspection Ready

Prof. Michael Schmitt
University Hospital Heidelberg

Dr Jan Schrooten
Antleron

Dr Astrid Schwantes
PEI, German Federal Agency for Vaccines and Biomedicines

Regulatory Requirements and Practical Implementation
Programme

Objective

This Live Online Conference provides a comprehensive overview of the current regulatory requirements for the development, manufacture and approval of Advanced Therapy Medicinal Products (ATMP). Representatives of regulatory authorities, experts from small-scale and large-scale production, QC laboratories and consultants will report on their practical experiences. From the construction of a new production facility to the introduction of a quality system and the final sterility test, all relevant topics directly related to ATMPs will be covered.

Background

Modern systems of regenerative medicines, especially ATMPs (gene therapeutics, somatic cell-based products and tissue-based products) represent an innovative group of drugs that is becoming increasingly important. With the introduction of several regulatory guidelines e.g. of the European Directive EC 1394/2007 for ATMP, such products were classified as medicinal products and must therefore comply as such with the EU requirements for medicinal products. Although the biopharmaceutical industry has considerably intensified its activities in this field, many of these products are developed and manufactured at universities, hospitals and in small- and medium-sized companies. These university or medical origins result in special challenges for the respective institutions as well as for the regulatory authorities in fulfilling the compliance requirements for quality, safety and GMP aspects and approval. This is also underlined by commonly occurring operating conditions, e.g. the open manipulation of cells and tissues, which are necessary for obtaining such products on a medical/surgical level or by the short shelf life of the obtained final product.

This results in a whole range of extraordinary requirements:
- the consideration of later requirements during development and in clinical phases
- the implementation of quality assurance requirements during aseptic production
- the use of alternative methods for analysis and microbiological control and the demonstration of comparability with conventional methods
- the handling of out of specification (OOS) / out of limit (OOL) results during product testing and the possibility of batch release

Target Audience

This Live Online Conference is aimed at all persons who
- Are involved in basic or translational research on cell-based therapy concepts with the perspective of clinical application
- Are involved in the extraction and manufacture of cells, tissues and ATMPs
- Are responsible for quality assurance and control of cells, tissues and ATMPs
- Are responsible for microbiological or analytical testing
- Perform inspections or audits of ATMP facilities
- Are responsible for GMP requirements during pre-approval phases
- Deal with authorisation

Programme Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 09.15 h</td>
<td>Welcome and Organisationalns</td>
</tr>
<tr>
<td>09.15 – 10.15 h</td>
<td>Regulatory Development</td>
</tr>
<tr>
<td>10.15 – 11.15 h</td>
<td>Challenges for Cell-Based Medicinal Products</td>
</tr>
<tr>
<td>11.15 – 11.30 h</td>
<td>Break</td>
</tr>
<tr>
<td>11.30 – 12.30 h</td>
<td>Risk-based Approach and Evaluation is the Leading Tool towards Manufacturing Authorization for iATMPs</td>
</tr>
<tr>
<td>12.30 – 13.00 h</td>
<td>Questions and Answers</td>
</tr>
<tr>
<td>13.00 – 14.00 h</td>
<td>Break</td>
</tr>
<tr>
<td>14.00-15.00 h</td>
<td>Cell by Design®, a Quality-Focused Process Development Roadmap for ATMP</td>
</tr>
<tr>
<td>15.00-16.00 h</td>
<td>A Case Study - Optimizing Manufacturing</td>
</tr>
</tbody>
</table>

Programme Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 10.15 h</td>
<td>Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)</td>
</tr>
<tr>
<td>10.15 – 11.15 h</td>
<td>Overview of the ATMP Development and Production Trends</td>
</tr>
<tr>
<td>11.15 – 12.15 h</td>
<td>Challenges and Regulatory Considerations</td>
</tr>
<tr>
<td>12.15 – 13.00 h</td>
<td>Break</td>
</tr>
<tr>
<td>13.00 – 14.00 h</td>
<td>Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)</td>
</tr>
<tr>
<td>14.00-15.00 h</td>
<td>Cell by Design®, a Quality-Focused Process Development Roadmap for ATMP</td>
</tr>
<tr>
<td>15.00-16.00 h</td>
<td>A Case Study - Optimizing Manufacturing</td>
</tr>
</tbody>
</table>
16.00 – 16.15 h Break

16.15 - 17.15 h
In-house Production of CAR-T Cells
- Requirements for hardware and procedures
- Regulatory affairs (with local/federal authorities)

17.15 – 18.00 h
Questions and Answers

Programme Day 2

08.30 – 09.15 h
ATMP Challenges for a QP
- A glimpse on the legal framework
- The complexity
- ATMP specific challenges
- What you should know about working with a QP

09.15 – 10.00 h
ATMP GMP Inspection Experiences
- Findings
- Pitfalls
- Hospital Exemption

10.00 – 10.15 h  Break

10.15 – 11.00 h
CAR-T Cells – Industrial Experiences

11.00 – 11.45 h
Strategies for Validating Nucleic Acid-based Techniques for Testing for the Absence of Mycoplasma
- NAT-Techniques
- Strategies for validation/suitability tests
- Pitfalls and practical examples

11.45 – 12.15 h
Questions and Answers

12.15 – 13.15 h  Break

13.15 – 14.00 h
Virus Safety Concepts for ATMPs
- Safety of raw and starting materials
- Serum and serum replacement(s) for cell based products
- Testing methodologies (NGS?)
- Virus inactivation and removal

14.00 – 15.00 h
Process Optimization for Individualized ATMPs - a Modern Aseptic Filling for Small Batches
- Hygiene monitoring in closed Isolators required?
- Regulatory challenges

15.00 – 15.15 h  Break

15.15 – 16.15 h
Treating Patients with OOS Batches - when Physicians Request Non-Conforming ATMPs
- Regulatory Framework
- Perspective and Expectations from Patients, Physicians, Sponsors, Manufacturers, QPs, Authorities - EU vs. US
- Batch Control, Review and Release Process

16.15 – 17.00 h
Questions and Answers

Moderator
Dr Andrea Hauser, Vice Chair ECA ATMP Interest Group, University Hospital Regensburg

Speakers

Dr Hans-Georg Eckert, Valicare GmbH, Germany
Dr Eckert is biologist by education and has more than 20 years of professional experience in accompanying and managing compliance tasks. After positions as Project Manager and Head of Quality, he has led Valicare since 2016 as Site Manager with special focus on ATP-GMP projects.

Dr Elena Ferber, Labor LS, Bad Bocklet
Elena studied Biology with the focus on biotechnology and pharmaceutical biology at the University of Würzburg. She worked on her dissertation at the department of Pharmaceutical Biology with a focus on molecular techniques. In 2018 she joined Labor LS, where she is the specialist manager in the department of molecular biology. There she is responsible for molecular biological analysis with the focus on microbiological identification and mycoplasma testing.

Dr Anette Jork, BioNTech, Germany
Dr Jork works as a Qualified Person for BioNTech since 2018. From 2001 to 2017 she worked for BTG International GmbH/CellMed AG in different functions e.g. Head of QC, QP and Director of Quality. She gained additional international experience in QM as part of her secondments from 2014 to 2017 in the UK and the US.
Dr Ilona Kalaszczyńska, Medical University of Warsaw
Ilona Kalaszczyńska is a graduate of the Faculty of Biology at the University of Warsaw. Since 2010, she is an associate professor at the Medical University of Warsaw. Since 2014, participated in or directed the process of accreditation of several cell/tissue banks - cord blood, bone allografts, and stem cell-based ATMPs. In 2016 she became a Quality Control Manager at the Laboratory for Cell Research and Application of the Medical University of Warsaw.

Dr Christoph Peter, BioNTech, Germany
Dr. Peter studied at the University of Heidelberg and gained his PhD at the Max-Planck Institute for Medical Research. After a postdoc fellowship at Stanford University, he joined Apceth, a CMO for cell based ATMPs in 2008 as Head of Production. 2011 he became Deputy QP and later Head of Quality Assurance. 2016 he came to BioNTech as Head of Quality and Deputy Qualified Person.

Dr Christoph Prinz, Head of Quality Assurance GMP, BioNTech
Dr Christoph Prinz is pharmacist and joined Novartis as Critical Deviation Investigator in 2011 before he changed to apceth Bio-pharma. Parallel to his work in the pharmaceutical development of new stem-cell based ATMPs, he increasingly took over responsibility in Quality Management. In 2018, he became Head of Quality Management and Qualified Person responsible for investigational and commercial ATMPs. Since 2020 he is with BioNTech.

Dr Christianne Reijnders, The Dutch Health and Youth Care Inspectorate
Christianne studied at the University of Utrecht Medical Biology and gained her PhD at the VU University Medical Centre (The Netherlands). Following she worked at the Leids University Medical Centre and at A-Skin Nederland B.V. In 2017 she became Senior Inspector at the Dutch Health and Youth Care Inspectorate (Netherlands) for GMP inspections.

Dr Ralf Sanzenbacher, Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines
Dr Sanzenbacher works at the Section of Somatic Cell Therapy and Tissue Engineering at the Paul-Ehrlich-Institut. He is an expert for regulatory aspects, as well as quality and preclinical issues aspects within the scope of manufacturing license, clinical trials and marketing authorisation. He is also member of several expert panels on cell therapies.

Mag. Gabriela Schallmeiner, INSPECTION-READY Consulting, Austria
Gabriela is a Founding Member and the Deputy Chair of the Austrian Qualified Person Association (www.austria-qp.at). Since 2007 she is running her own GxP Consultancy Services Company. She works as a QP in Austria and in Germany for ATMPs, vaccines and immunological products.
Prof Dr Michael Schmitt, University Clinic and University of Heidelberg, Germany
Michael Schmitt obtained his MD from the University of the Saarland, Homburg, Germany. He is currently Siebeneicher-Endowment Professor of Cellular Immunotherapy and Head of the Good Manufacturing Practice (GMP) Facility at the University Clinic Heidelberg, Germany.

Dr. ir. Jan Schrooten, Antleron, Belgium
Antleron is a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. Previously, Jan Schrooten was senior research manager at KU Leuven (Belgium), responsible for the long-term management and technology transfer of biomaterials and tissue engineering research.

Dr Astrid Schwantes, Paul Ehrlich Institut, German Federal Agency for Vaccines and Biomedicines
Astrid Schwantes studied Biology at the University Mainz. 2003 she joined the Division of Virology at the Paul-Ehrlich Institut. Since 2013 she is regulatory assessor at the section virus safety at the PEI.

Your Benefits

Internationally Acknowledged Certificate from ECA Academy
The EU GMP Guide requires: “… All personnel should be aware of the principles of Good Manufacturing Practice that affect them and receive initial and continuing training…” This is why you receive an acknowledged participant certificate, which lists the contents of the seminar in detail and with which you document your training.

This Training Course is recognized for the GMP/GDP Certification Scheme
Building on your education the ECA GMP/GDP certification programmes provide you with the appropriate supplement to acquire this qualification. This training course is the first element for your additional certification. Simply choose any three courses within the programme according to your professional interest. Your certificate is then valid for two years. To renew it, you can pick any training from the ECA courses and conferences list within that two-years period – allowing you to broaden your knowledge in GMP and GDP compliance. Please find more information at www.gmp-certification.org
Reservation Form (Please complete in full)

Quality, Safety and GMP for Advanced Therapy Medicinal Products (ATMPs)
Live Online Conference on 10/11 November 2020

Title, first name, surname

Department

Company

Important: Please indicate your company’s VAT ID Number

Purchase Order Number, if applicable

City

ZIP Code

Country

Phone / Fax

E-Mail (Please fill in)

Date of the Live Online Conference

Tuesday, 10 November 2020, 09.00 – 18.00 h CET

Wednesday 11 November 2020, 08.30 – 17.00 h CET

Technical Requirements

For our webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.

At http://www.webex.com/test-meeting.html you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and e-mail address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate, plus VAT)

ECA Members € 1,590

APIC Members € 1,690

Non-ECA Members € 1,790

EU GMP Inspectorates € 895

Academic Scientists/ Students € 895

The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax message.

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

Mr Axel H. Schroeder (Operations Director) at +49(0)62 21/84 44 10, or at schroeder@concept-heidelberg.de.

For questions regarding organisation please contact:

Mr Niklaus Thiel (Organisation Manager) at +49(0)62 21/84 44 43, or at thiel@concept-heidelberg.de.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.

WA/23072020